Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zymeworks Inc ZYME

Healthcare Biotechnology
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based... see more

Recent & Breaking News (NDAQ:ZYME)

Zymeworks Files Preliminary Prospectus Supplement for Offering of Common Shares

Business Wire June 6, 2018

IIROC Trade Resumption - ZYME

Canada NewsWire June 1, 2018

IIROC Trading Halt - ZYME

Canada NewsWire June 1, 2018

Clinical Data for Zymeworks’ Novel Bispecific Antibody, ZW25, Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

Business Wire June 1, 2018

Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies

Business Wire May 14, 2018

Zymeworks to Present at the UBS Global Healthcare Conference 2018

Business Wire May 10, 2018

Zymeworks Reports 2018 First Quarter Financial Results

Business Wire May 1, 2018

Zymeworks to Present at Bloom Burton & Co. Healthcare Investor Conference 2018

Business Wire April 30, 2018

Zymeworks Announces Selection of ZW25 Abstract for Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting

Business Wire April 25, 2018

Zymeworks and Celgene Expand Bispecific Antibody Collaboration

Business Wire April 23, 2018

Zymeworks Presents Preclinical Data at the Annual Meeting of the American Association for Cancer Research

Business Wire April 17, 2018

Zymeworks Advances Clinical Candidate Incorporating Technology from Kairos Acquisition

Business Wire March 14, 2018

Zymeworks Reports 2017 Year-End Financial Results

Business Wire March 14, 2018

Zymeworks to Present at Barclays 2018 Global Healthcare Conference

Business Wire March 7, 2018

Zymeworks Opening Clinical Sites in Canada

Business Wire February 28, 2018

Zymeworks Highlights Key 2017 Accomplishments and Announces 2018 Priorities

Business Wire January 7, 2018

Lifshitz & Miller LLP Announces Investigation of Alon USA Partners, LP, Amplify Snack Brands, Inc., Kindred Healthcare, Inc., Pinnacle Entertainment, Inc., Regal Entertainment Group, Sigma Designs, Inc. and Zymeworks Inc.

PR Newswire December 28, 2017

ZYME INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Zymeworks Inc. Investors

Business Wire December 20, 2017

Zymeworks (ZYME) Alert: Johnson Fistel Announces Investigation of Zymeworks Inc.; Encourages Investors to Contact the Firm for Additional Information

PR Newswire December 15, 2017

Zymeworks Presents Results of the Completed Dose Escalation Portion of the Ongoing Phase 1 Study of ZW25 at the San Antonio Breast Cancer Symposium

Business Wire December 5, 2017